Cargando…

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is poorly understood and therapeutic strategies are lacking. This study aimed to identify plasma proteins with pathophysiological relevance in HFpEF and with respect to spironolactone-induced effects. We assessed 92 biomar...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnelle, Moritz, Leha, Andreas, Eidizadeh, Abass, Fuhlrott, Katharina, Trippel, Tobias D., Hashemi, Djawid, Toischer, Karl, Wachter, Rolf, Herrmann-Lingen, Christoph, Hasenfuß, Gerd, Pieske, Burkert, Binder, Lutz, Edelmann, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535031/
https://www.ncbi.nlm.nih.gov/pubmed/34685778
http://dx.doi.org/10.3390/cells10102796
_version_ 1784587679632982016
author Schnelle, Moritz
Leha, Andreas
Eidizadeh, Abass
Fuhlrott, Katharina
Trippel, Tobias D.
Hashemi, Djawid
Toischer, Karl
Wachter, Rolf
Herrmann-Lingen, Christoph
Hasenfuß, Gerd
Pieske, Burkert
Binder, Lutz
Edelmann, Frank
author_facet Schnelle, Moritz
Leha, Andreas
Eidizadeh, Abass
Fuhlrott, Katharina
Trippel, Tobias D.
Hashemi, Djawid
Toischer, Karl
Wachter, Rolf
Herrmann-Lingen, Christoph
Hasenfuß, Gerd
Pieske, Burkert
Binder, Lutz
Edelmann, Frank
author_sort Schnelle, Moritz
collection PubMed
description The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is poorly understood and therapeutic strategies are lacking. This study aimed to identify plasma proteins with pathophysiological relevance in HFpEF and with respect to spironolactone-induced effects. We assessed 92 biomarkers in plasma samples from 386 HFpEF patients—belonging to the Aldo-DHF trial—before (baseline, BL) and after one-year treatment (follow up, FU) with spironolactone (verum) or a placebo. At BL, various biomarkers showed significant associations with the two Aldo-DHF primary end point parameters: 33 with E/e’ and 20 with peak VO(2). Ten proteins including adrenomedullin, FGF23 and inflammatory peptides (e.g., TNFRSF11A, TRAILR2) were significantly associated with both parameters, suggesting a role in the clinical HFpEF presentation. For 13 proteins, expression changes from BL to FU were significantly different between verum and placebo. Among them were renin, growth hormone, adrenomedullin and inflammatory proteins (e.g., TNFRSF11A, IL18 and IL4RA), indicating distinct spironolactone-mediated effects. BL levels of five proteins, e.g., inflammatory markers such as CCL17, IL4RA and IL1ra, showed significantly different effects on the instantaneous risk for hospitalization between verum and placebo. This study identified plasma proteins with different implications in HFpEF and following spironolactone treatment. Future studies need to define their precise mechanistic involvement.
format Online
Article
Text
id pubmed-8535031
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85350312021-10-23 Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial Schnelle, Moritz Leha, Andreas Eidizadeh, Abass Fuhlrott, Katharina Trippel, Tobias D. Hashemi, Djawid Toischer, Karl Wachter, Rolf Herrmann-Lingen, Christoph Hasenfuß, Gerd Pieske, Burkert Binder, Lutz Edelmann, Frank Cells Article The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is poorly understood and therapeutic strategies are lacking. This study aimed to identify plasma proteins with pathophysiological relevance in HFpEF and with respect to spironolactone-induced effects. We assessed 92 biomarkers in plasma samples from 386 HFpEF patients—belonging to the Aldo-DHF trial—before (baseline, BL) and after one-year treatment (follow up, FU) with spironolactone (verum) or a placebo. At BL, various biomarkers showed significant associations with the two Aldo-DHF primary end point parameters: 33 with E/e’ and 20 with peak VO(2). Ten proteins including adrenomedullin, FGF23 and inflammatory peptides (e.g., TNFRSF11A, TRAILR2) were significantly associated with both parameters, suggesting a role in the clinical HFpEF presentation. For 13 proteins, expression changes from BL to FU were significantly different between verum and placebo. Among them were renin, growth hormone, adrenomedullin and inflammatory proteins (e.g., TNFRSF11A, IL18 and IL4RA), indicating distinct spironolactone-mediated effects. BL levels of five proteins, e.g., inflammatory markers such as CCL17, IL4RA and IL1ra, showed significantly different effects on the instantaneous risk for hospitalization between verum and placebo. This study identified plasma proteins with different implications in HFpEF and following spironolactone treatment. Future studies need to define their precise mechanistic involvement. MDPI 2021-10-19 /pmc/articles/PMC8535031/ /pubmed/34685778 http://dx.doi.org/10.3390/cells10102796 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schnelle, Moritz
Leha, Andreas
Eidizadeh, Abass
Fuhlrott, Katharina
Trippel, Tobias D.
Hashemi, Djawid
Toischer, Karl
Wachter, Rolf
Herrmann-Lingen, Christoph
Hasenfuß, Gerd
Pieske, Burkert
Binder, Lutz
Edelmann, Frank
Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
title Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
title_full Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
title_fullStr Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
title_full_unstemmed Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
title_short Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
title_sort plasma biomarker profiling in heart failure patients with preserved ejection fraction before and after spironolactone treatment: results from the aldo-dhf trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535031/
https://www.ncbi.nlm.nih.gov/pubmed/34685778
http://dx.doi.org/10.3390/cells10102796
work_keys_str_mv AT schnellemoritz plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT lehaandreas plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT eidizadehabass plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT fuhlrottkatharina plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT trippeltobiasd plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT hashemidjawid plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT toischerkarl plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT wachterrolf plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT herrmannlingenchristoph plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT hasenfußgerd plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT pieskeburkert plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT binderlutz plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial
AT edelmannfrank plasmabiomarkerprofilinginheartfailurepatientswithpreservedejectionfractionbeforeandafterspironolactonetreatmentresultsfromthealdodhftrial